Professional Documents
Culture Documents
probiotics
Probiotics1 (for life)
probiotics
40
, - 2557
(cocktails probiotic)
probiotics
( 1)
prebiotics
(fermented)
prebiotics oligosaccharides
Bifidobacteria Lactobacilli
inulin-type fructans, fructo-oligosaccharide
lactulose
Synbiotics probiotics
prebiotics probiotics
1 Probiotics
Lactomin
Intestis-flora7
Pro-digest
TS6
(/)
Lactobacillus acidophilus
2 x109 CFU
109 CFU
Lactobacillus spp.
Bifidobacterium spp.
Streptococus spp.
Lactobacillus spp.
Bifidobacterium spp.
2 x1010 CFU
Lactobacillus spp.
Bifidobacterium spp.
16 / sachet
40 / stick
25 / capsule
38 / sachet
41
Bifidobacteria Lactobacilli
(Microbiota)
(peristalsis)
33
109 CFU/mL (terminal ileum) 1012 CFU/
mL
1 ( 1)
1
42
, - 2557
1. (nutrition)
lactose alcohol
bacterial disaccharidases short chain fatty acids
(SCFAs)
2.
(integrity of epithelial barrier and mucosal immunity)
peroxides bacteriocin
2,3
Rome III4
3
5
Probiotics and Irritable bowel syndrome
43
(flatulence)
(bloating) (fermentation)
( 2)
(luminal microbiota)
Kassinen 22
27 real-time PCR
Lactobacilli Bifidobacteria
IBS-D IBS-C Enterobacteraciaceae,
Coliform Bacteroides IBS6
IBS IBS
2
44
, - 2557
Lactobacilli Bifidobacteria
IBS 2
(mucosa-associated microbiota)
biofilm glycosylated
polysaccharides glycocalyx
pattern recognition receptors (PRRs) toll-like receptors (TLRs) apical basolateral
membrane enterocytes laminar propria dendritic cell
Bifidobacteria Lactobacilli
anti-inflammatory cytokines interleukin (IL-10) transforming
growth factor beta (TGF-) proinflammatory cytokines
7
1. bacteriocin
2. mucin
defensins
3. TLRs (
3)
probiotics
probiotics
Probiotics and Irritable bowel syndrome
45
3 probiotics
46
, - 2557
()
Mc Farland et al8
2008
20 (1,414)
Hoyveda et al9
2009
14 (1,593)
Brenner et al10
2009
16 (1,342)
Moayyedi et al11
2010
20 (1628)
RCT, randomized control trial; RR, relative risk; OR, odds ratio; SMD, standardized mean difference
47
(bloating/distension)
IL-10:IL-12
B. infantis probiotics
OMahoney
Whorwell13 double blind RCT 293
B. infantis 35624 106, 108
1010 CFU/mL 4 6
6-point Likert scale B.
infantis 108 CFU/mL
1010 CFU/mL
B. infantis 35624
IBS 108 CFU/mL
Bifidobacterium animalis
Guyonnet14 double blind RCT IBD-C
267 B. animalis 1.25x1010 CFU
48
, - 2557
Week 3
Week 6
Baseline
Week 3
Week 6
Score (0-100)
49.7 18.8 60.8 18.1 62.0 18.4 52.5 18.2 59.9 17.9 65.8 18.9
Change from baseline
10.7 14.5 12.2 16.2
7.5 14.7 13.5 19.3
Lactobacillus plantarum
Niedzielin15 double blind RCT IBS
40 L. plantarum 299V 5x107 CFU/mL
4
(p=0.0012) L. plantarum arginine
Probiotics and Irritable bowel syndrome
49
nitric oxide
VSL number 3
VSL No.3 probiotics cocktail
lyophilized Bifidobacterium (B.
longum, B. infantis, B. breve) Lactobacillus (L. acidophilus, L. casei, L.
bulgaricus, L. plantarum) Streptococcus sailvarious thermophilus
Kim16 parallel group, double blind RCT
IBS 48 ( 100-mm visual analogue scale (VAS) abdominal bloating 24) VSL No.3
450 /
4 8 VAS
probiotics
(flatulence) 4 (p=0.014)
(p=0.011) colonic transit
111In charcoal (p=0.05)
probiotics pro-inflammatory cytokines
Bifidobacteria infantis B5624 VSL No.3 B
50
, - 2557
1.
2. probiotics
3. probiotics
probiotics
probiotics
Boyle, Robins-Browne Tang ..200618
systematic review probiotics
.. 201019 probiotics
Lactobacillus rhamnosus20
Lactobacillus rhamnosus 21
probiotics
probiotics
probiotics
probiotics
Lactobacillus reuteri
22
Probiotics and Irritable bowel syndrome
51
probiotics
central venous catheter probiotics jejunostomy broad spectrum antibiotic probiotics
Lactobacillus
Probiotics
probiotics Bifidobacterium infantis
35624, Lactobacillus plantarum Bifidobacterium
animalis IBS-C
3 / VSL No.3
probiotics
1. Quigley EM. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol
Clin North Am. 2011;40:207-22.
2. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in
irritable bowel syndrome: their role in its pathogenesis and treatment. Am J
Gastroenterol. 2008;103:1557-67.
3. Bolino CM, Bercik P. Pathogenic factors involved in the development of irritable
bowel syndrome: focus on a microbial role. Infect Dis Clin North Am. 2010;24:96175, ix.
4. Halder SL, Talley NJ. Functional Dyspepsia: A New Rome III Paradigm. Curr
Treat Options Gastroenterol. 2007;10(4):259-72.
52
, - 2557
5. Kellow JE, Azpiroz F, Delvaux M, Gebhart GF, Mertz HR, Quigley EM, et al.
Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology. 2006;130:1412-20.
6. Kassinen A, Krogius_Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J,
et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24-33.
7. Shanahan F. Probiotics in perspective. Gastroenterology. 2010;139:1808-12.
8. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14:2650-61.
9. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A
systematic review and meta-analysis: probiotics in the treatment of irritable
bowel syndrome. BMC Gastroenterol. 2009;9:15.
10. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in
the treatment of irritable bowel syndrome: a systematic review. Am J
Gastroenterol. 2009;104:1033-49; quiz 1050.
11. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et
al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a
systematic review. Gut. 2010;59:325-32.
12. OMahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus
and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-51.
13. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, OMahony L, et al.
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women
with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581-90.
14. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al.
Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on
the health-related quality of life and symptoms in irritable bowel syndrome in
adults in primary care: a multicentre, randomized, double-blind, controlled trial.
Aliment Pharmacol Ther. 2007;26:475-86.
15. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized
Probiotics and Irritable bowel syndrome
53
16.
17.
18.
19.
20.
21.
22.
54
, - 2557